NVS
Novartis AG
Set alert
- YTD
- +16.62%
- 1 year
- +31.14%
- Open
- 162.53
- Prev close
- 161.10
- Mkt cap
- 303.67B
- Vol
- 3.15M
- Avg vol
- 2.02M
- EPS
- 5.24
- P/E
- 30.69
- Div yield
- 2.94%
More statistics
- Low
- 160.42
- High
- 164.06
- Forward P/E
- 16.23
- Beta
- 0.47
- Short ratio
- 3.01
- Inst. own
- 7.31%
- Dividend
- 4.74
- Ex-div date
- Mar 10, 2026
- Earnings
- Feb 3, 2027
- 50-d avg
- 148.31
- 200-d avg
- 151.74
- 1y target
- 155.29
Key statistics
- Market cap
- 303.71B
- Enterprise value
- 344.03B
- Trailing P/E
- 30.69
- Forward P/E
- 16.23
- PEG ratio
- 3.85
- Price / sales
- 5.29
- Price / book
- 8.16
- EPS (TTM)
- 5.24
- Beta
- 0.47
- Dividend yield
- 2.94%
- Payout ratio
- 90.46%
- Profit margin
- 17.49%
- Revenue (TTM)
- 57.36B
- Revenue growth
- 4.70%
- Free cash flow
- 11.27B
- Total cash
- 8.87B
- Total debt
- 48.31B
- Return on equity
- 24.33%
- Shares outstanding
- 1.89B
- Short % of float
- 0.30%
- 50-day average
- 148.31
- 200-day average
- 151.74
Analyst view
Consensus: hold
- Target (low)
- 130.00
- Target (mean)
- 155.29
- Target (high)
- 185.00
- Strong buy3
- Buy2
- Hold5
- Sell1
- Strong sell1
Next earnings
Feb 3, 2027
Expected Feb 3, 2027. Consensus EPS estimate 2.23.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 3, 2027 | Dec 30, 2026 | 2.23 | — | — | — |
| Oct 27, 2026 | Sep 30, 2026 | 2.25 | 2.46 | +0.21 | +9.33% |
| Jul 21, 2026 | Jun 30, 2026 | 2.17 | 2.41 | +0.24 | +11.06% |
| Apr 28, 2026 | Mar 31, 2026 | 2.11 | 1.99 | -0.12 | -5.69% |
| Feb 4, 2026 | Dec 31, 2025 | 1.99 | 2.03 | +0.04 | +2.01% |
| Oct 28, 2025 | Sep 29, 2025 | 2.26 | 2.25 | -0.01 | -0.44% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Deutsche Bank | down | Hold | Sell |
| Sep 10, 2026 | HSBC | up | Reduce | Hold |
| Mar 26, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Jan 6, 2026 | Barclays | up | Underweight | Equal-Weight |
| Dec 8, 2025 | JP Morgan | up | Neutral | Overweight |
| Sep 12, 2025 | Goldman Sachs | down | Neutral | Sell |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- Switzerland
- Website
- novartis.com
News
- Novartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced Approach
- All You Need to Know About Novartis (NVS) Rating Upgrade to Buy
- Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
- A pharma giant is moving past one patent cliff — but another is already looming
- Novartis AG (NVS) Q3 2026 Earnings Call Transcript
- These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
- Monte Rosa To Receive $37.5M Milestone Payment From Novartis Following Initiation Of Second Phase 2 Trial Of MRT-6160 In Psoriatic Arthritis
- Monte Rosa Says Its Collaborator Novartis Initiates Second Phase 2 Clinical Study For VAV1-Directed MGD MRT-6160 In People Living With Active Moderate To Severe Psoriatic Arthritis
- What Novartis (NVS) Said on Its Q3 Earnings Call
- 4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential
Your note
Sign in to keep a note on NVS — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fisher Asset Management, LLC | 0.76% | 15,523,378 | 2.50B | Jun 29, 2026 |
| Morgan Stanley | 0.43% | 8,726,827 | 1.40B | Jun 29, 2026 |
| Dimensional Fund Advisors LP | 0.40% | 8,117,586 | 1.31B | Jun 29, 2026 |
| Primecap Management Company | 0.32% | 6,592,124 | 1.06B | Jun 29, 2026 |
| LOOMIS SAYLES & CO L P | 0.26% | 5,239,309 | 842.53M | Jun 29, 2026 |
| Bank of America Corporation | 0.24% | 4,909,938 | 789.57M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund | 0.21% | 4,252,875 | 683.90M | Jun 29, 2026 |
| DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT. | 0.10% | 2,060,639 | 331.37M | Jul 30, 2026 |
| LOOMIS SAYLES FUNDS II-Loomis Sayles Growth Fund | 0.07% | 1,417,894 | 228.01M | Jun 29, 2026 |
| VANGUARD HORIZON FUNDS-Vanguard Capital Opportunity Fund | 0.06% | 1,211,220 | 194.78M | Jun 29, 2026 |
| Franklin Mutual Series Funds-FRANKLIN MUTUAL GLOBAL DISCOVERY FUND | 0.06% | 1,192,174 | 191.71M | Jun 29, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 0.05% | 949,726 | 152.73M | Jun 29, 2026 |